116 related articles for article (PubMed ID: 21860427)
1. Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome.
Yoshihara S; Ikegame K; Kaida K; Taniguchi K; Kato R; Inoue T; Fujioka T; Tamaki H; Okada M; Soma T; Ogawa H
Bone Marrow Transplant; 2012 May; 47(5):669-76. PubMed ID: 21860427
[TBL] [Abstract][Full Text] [Related]
2. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Shimizu H; Saitoh T; Hatsumi N; Takada S; Handa H; Jimbo T; Sakura T; Miyawaki S; Nojima Y
Leuk Res; 2013 Nov; 37(11):1477-81. PubMed ID: 24054717
[TBL] [Abstract][Full Text] [Related]
4. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse.
Solh M; DeFor TE; Weisdorf DJ; Kaufman DS
Biol Blood Marrow Transplant; 2012 Jan; 18(1):106-12. PubMed ID: 21703975
[TBL] [Abstract][Full Text] [Related]
5. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
6. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
7. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia.
Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Ryu SG; Park CJ; Chi HS; Lee MS; Yun S; Lee JS; Lee KH
Haematologica; 2005 Oct; 90(10):1380-8. PubMed ID: 16219575
[TBL] [Abstract][Full Text] [Related]
8. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation.
Simpson DR; Nevill TJ; Shepherd JD; Fung HC; Horsman DE; Nantel SH; Vickars LM; Sutherland HJ; Toze CL; Hogge DE; Klingemann HG; Naiman SC; Barnett MJ
Bone Marrow Transplant; 1998 Aug; 22(3):259-64. PubMed ID: 9720739
[TBL] [Abstract][Full Text] [Related]
9. T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.
Devillier R; Bramanti S; Fürst S; Sarina B; El-Cheikh J; Crocchiolo R; Granata A; Chabannon C; Morabito L; Harbi S; Faucher C; Santoro A; Weiller PJ; Vey N; Carlo-Stella C; Castagna L; Blaise D
Bone Marrow Transplant; 2016 Feb; 51(2):194-8. PubMed ID: 26551778
[TBL] [Abstract][Full Text] [Related]
10. Is extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation associated with improved survival?
Curley C; Durrant S; Kennedy GA
Asia Pac J Clin Oncol; 2013 Sep; 9(3):285-9. PubMed ID: 23418909
[TBL] [Abstract][Full Text] [Related]
11. Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
[TBL] [Abstract][Full Text] [Related]
12. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome.
Mo XD; Xu LP; Zhang XH; Liu DH; Wang Y; Chen H; Yan CH; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Bone Marrow Transplant; 2015 Jan; 50(1):127-33. PubMed ID: 25387095
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
[TBL] [Abstract][Full Text] [Related]
14. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Czibere A; Bruns I; Kröger N; Platzbecker U; Lind J; Zohren F; Fenk R; Germing U; Schröder T; Gräf T; Haas R; Kobbe G
Bone Marrow Transplant; 2010 May; 45(5):872-6. PubMed ID: 19820729
[TBL] [Abstract][Full Text] [Related]
15. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Devillier R; Crocchiolo R; Castagna L; Fürst S; El Cheikh J; Faucher C; Prebet T; Etienne A; Chabannon C; Vey N; Esterni B; Blaise D
Bone Marrow Transplant; 2012 May; 47(5):639-45. PubMed ID: 22307016
[TBL] [Abstract][Full Text] [Related]
16. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.
Sauer T; Silling G; Groth C; Rosenow F; Krug U; Görlich D; Evers G; Albring J; Besoke R; Mesters RM; Müller-Tidow C; Kessler T; Büchner T; Berdel WE; Stelljes M
Bone Marrow Transplant; 2015 Apr; 50(4):485-92. PubMed ID: 25599163
[TBL] [Abstract][Full Text] [Related]
18. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Bernal T; Diez-Campelo M; Godoy V; Rojas S; Colado E; Alcoceba M; González M; Vidriales B; Sánchez-Guijo FM; López-Corral L; Luño E; del Cañizo C
Leuk Res; 2014 May; 38(5):551-6. PubMed ID: 24655806
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
